On-demand webinar
The GLP-1 cost crisis: What can you do?
The GLP-1 cost crisis: What can you do?
About the webinar
Some of the largest organizations in the US spend upwards of $16,000 per person per year on costs associated with GLP-1s.
How much are you willing to spend on GLP-1s annually?
Regardless of company or plan size, the costs associated with these life-changing anti-obesity medications are astounding and often unmanaged. Leaders walk a fine line between wanting to offer the best care for obesity — one of America’s most prevalent chronic health conditions — and needing to be fiscally responsible.
The good news is you don’t have to pull never-ending dollars from your coffers to give care at the right time to your people. Obesity step therapy is a clinically-proven treatment that provides acuity-based treatment — meaning if you need a GLP-1, you’ll be prescribed one, but if you don’t, a provider will recommend the right treatment.
In this webinar, Vida’s own Sr. Director of Cardiometabolic and Prescribing, Gretchen Zimmermann, joined Chief Medical Officer Dr. Richard Frank to discuss:
- What obesity step therapy is and how it can dramatically reduce GLP-1 costs
- How GLP-1 and other anti-obesity medications can be properly managed without costly lifetime prescriptions
- Why step therapy helps organizations sustain and scale clinical and engagement outcomes
Featured speakers
Dr. Richard Frank
Chief Medical Officer
at Vida
Gretchen Zimmermann
VP of Clinical Strategy
at Vida
Curious to read more?
How to get obesity outcomes without breaking the bank explores how a step-therapy approach to obesity management can use behavior change and prescription management for the best outcomes.